BR112017009545A2 - composição antibacteriana, método para a preparação de uma composição, bacteriófago, ácido nucleico isolado, polipeptídeo isolado, e uso de um bacteriófago, ácido nucleico ou polipeptídeo - Google Patents

composição antibacteriana, método para a preparação de uma composição, bacteriófago, ácido nucleico isolado, polipeptídeo isolado, e uso de um bacteriófago, ácido nucleico ou polipeptídeo

Info

Publication number
BR112017009545A2
BR112017009545A2 BR112017009545A BR112017009545A BR112017009545A2 BR 112017009545 A2 BR112017009545 A2 BR 112017009545A2 BR 112017009545 A BR112017009545 A BR 112017009545A BR 112017009545 A BR112017009545 A BR 112017009545A BR 112017009545 A2 BR112017009545 A2 BR 112017009545A2
Authority
BR
Brazil
Prior art keywords
bacteriophage
nucleic acid
polypeptide
composition
isolated
Prior art date
Application number
BR112017009545A
Other languages
English (en)
Other versions
BR112017009545B8 (pt
BR112017009545B1 (pt
Inventor
Pouillot Flavie
Blois Hélène
Original Assignee
Pherecydes Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pherecydes Pharma filed Critical Pherecydes Pharma
Publication of BR112017009545A2 publication Critical patent/BR112017009545A2/pt
Publication of BR112017009545B1 publication Critical patent/BR112017009545B1/pt
Publication of BR112017009545B8 publication Critical patent/BR112017009545B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção se refere à terapia com bacteriófagos. mais particularmente, a presente invenção se refere a novos bacteriófagos que têm uma especificidade elevada contra cepas de pseudomonas aeruginosa, sua produção, componentes dos mesmos, composições que compreendem os mesmos e usos dos mesmos em terapia com fagos.
BR112017009545A 2014-11-07 2015-11-06 Composição antibacteriana farmacêutica ou veterinária e método in vitro para a preparação de uma composição farmacêutica ou veterinária BR112017009545B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14306788.6 2014-11-07
EP14306788.2A EP3018201A1 (en) 2014-11-07 2014-11-07 Phage therapy
PCT/EP2015/075949 WO2016071503A1 (en) 2014-11-07 2015-11-06 Phage therapy

Publications (3)

Publication Number Publication Date
BR112017009545A2 true BR112017009545A2 (pt) 2018-02-14
BR112017009545B1 BR112017009545B1 (pt) 2024-01-02
BR112017009545B8 BR112017009545B8 (pt) 2024-01-23

Family

ID=51947284

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009545A BR112017009545B8 (pt) 2014-11-07 2015-11-06 Composição antibacteriana farmacêutica ou veterinária e método in vitro para a preparação de uma composição farmacêutica ou veterinária

Country Status (16)

Country Link
US (2) US10898530B2 (pt)
EP (2) EP3018201A1 (pt)
JP (1) JP6894376B2 (pt)
CN (1) CN107429236A (pt)
AU (1) AU2015341683B2 (pt)
BR (1) BR112017009545B8 (pt)
CA (1) CA2966944A1 (pt)
DK (1) DK3215607T3 (pt)
ES (1) ES2926129T3 (pt)
HU (1) HUE060113T2 (pt)
IL (1) IL251976B (pt)
LT (1) LT3215607T (pt)
PL (1) PL3215607T3 (pt)
PT (1) PT3215607T (pt)
SI (1) SI3215607T1 (pt)
WO (1) WO2016071503A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2893933A1 (en) 2014-01-10 2015-07-15 Pherecydes Pharma Phage Therapy of E coli infections
EP3018201A1 (en) * 2014-11-07 2016-05-11 Pherecydes Pharma Phage therapy
EP3372085A1 (en) 2017-03-08 2018-09-12 Pherecydes Pharma Phage therapy
US20210361727A1 (en) * 2018-01-02 2021-11-25 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating pseudomonas infections
EP3860632A4 (en) * 2018-10-04 2022-08-17 Western Sydney Local Health District BACTERIOPHAGOUS TREATMENT AND REDUCTION OF THE INFLAMMATORY RESPONSE
WO2020137421A1 (ja) 2018-12-27 2020-07-02 国立大学法人岐阜大学 宿主細菌特異的ナノ粒子
WO2021222257A1 (en) * 2020-04-27 2021-11-04 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating pseudomonas infection
AU2022247325A1 (en) * 2021-03-30 2023-10-05 Biomx Ltd. Pseudomonas bacteriophage and uses thereof
WO2023044068A1 (en) * 2021-09-16 2023-03-23 The Board Of Trustees Of The Leland Stanford Junior University Bacteriophages for protection from ultraviolet irradiation
EP4265263A1 (en) * 2022-04-19 2023-10-25 Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz Bacteriophage suitable for treating a bacterial infection caused by pseudomonas aeruginosa

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1305038B1 (en) 2000-07-25 2005-10-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Bacteriophage having multiple host range
WO2009075884A1 (en) 2007-12-12 2009-06-18 Intralytix, Inc. Novel e. coli bacteriophages and uses thereof
JP6058540B2 (ja) * 2010-09-17 2017-01-11 テクニファー−インダストリア テクニカ ファーマシューティカ，エス．エー． 抗菌性ファージ、ファージペプチド、及びそれらの使用方法
CN102199576B (zh) * 2010-11-23 2012-09-19 天津科技大学 降解铜绿假单胞菌生物被膜噬菌体的分离与筛选方法
EP2465926A1 (en) 2010-12-20 2012-06-20 University College Cork Pseudomonas aeruginosa Bacteriophage and uses thereof
CN104140957B (zh) * 2013-05-07 2017-04-26 兰州大学 一株可裂解多重耐药铜绿假单胞菌的噬菌体及其治疗感染的应用
EP2865383A1 (en) 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
EP2893933A1 (en) 2014-01-10 2015-07-15 Pherecydes Pharma Phage Therapy of E coli infections
EP3018201A1 (en) * 2014-11-07 2016-05-11 Pherecydes Pharma Phage therapy

Also Published As

Publication number Publication date
BR112017009545B8 (pt) 2024-01-23
PT3215607T (pt) 2022-09-16
ES2926129T3 (es) 2022-10-24
EP3018201A1 (en) 2016-05-11
US20210228659A1 (en) 2021-07-29
AU2015341683B2 (en) 2021-12-02
JP2017534684A (ja) 2017-11-24
AU2015341683A1 (en) 2017-05-18
US11779617B2 (en) 2023-10-10
BR112017009545B1 (pt) 2024-01-02
LT3215607T (lt) 2022-11-10
WO2016071503A8 (en) 2017-06-29
WO2016071503A1 (en) 2016-05-12
IL251976A0 (en) 2017-06-29
SI3215607T1 (sl) 2022-11-30
US10898530B2 (en) 2021-01-26
IL251976B (en) 2020-02-27
JP6894376B2 (ja) 2021-06-30
US20170319637A1 (en) 2017-11-09
PL3215607T3 (pl) 2022-11-07
CA2966944A1 (en) 2016-05-12
EP3215607A1 (en) 2017-09-13
EP3215607B1 (en) 2022-07-13
CN107429236A (zh) 2017-12-01
DK3215607T3 (da) 2022-09-05
HUE060113T2 (hu) 2023-01-28

Similar Documents

Publication Publication Date Title
BR112017009545A2 (pt) composição antibacteriana, método para a preparação de uma composição, bacteriófago, ácido nucleico isolado, polipeptídeo isolado, e uso de um bacteriófago, ácido nucleico ou polipeptídeo
BR112018077266A2 (pt) composições compreendendo cepas bacterianas
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
BR112018070859A2 (pt) degradantes da proteína de bet
BR112016024644A2 (pt) vacinas de ácido nucleico
PE20180267A1 (es) Composiciones que comprenden cepas bacterianas
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
EA201691582A1 (ru) Новые фармацевтические препараты
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
TR201908550T4 (tr) Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
BR112016009062A2 (pt) Composição antibacteriana, método para a preparação de uma composição, método para prever ou determinar a eficácia de uma terapia de bacteriófago em um indivíduo, método para selecionar um indivíduo ou determinar se um indivíduo é susceptível de se beneficiar de uma terapia com bacteriófagos, bacteriófago, ácido nucleico isolado, e, polipeptídeo isolado
BR112017002370A2 (pt) indóis para uso na infecção pelo vírus da gripe
BR112017009277A2 (pt) compostos de silicone
BR112017020935A2 (pt) ?compostos, composição farmacêutica e conjunto?
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
BR112016016853A2 (pt) Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso
PH12016501988A1 (en) Antibacterial compounds
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
EA201890186A1 (ru) Применение штаммов микробактерий для получения антибактериальных агентов
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/11/2015, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2765 DE 02/01/2024 QUANTO A PRIORIDADE UNIONISTA.